INTRODUCTION
Tuberculosis remains an important cause of morbidity and mortality worldwide. [1] The current vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), has variable protective efficacy ranging from 0 to 85% in different studies [2] , hence, efforts are being made in order to develop an improved vaccine. As for many pathogens, M. tuberculosis infection occurs through mucosa. Therefore, the development of an efficient vaccine will require an appropriate antigen presentation and adjuvant effect that can induce both mucosal and systemic immune response, preventing not only infectious disease but also colonization of mucosal surfaces [3] .
Biodegradable particulate delivery systems have been successfully used in recent vaccine development, and mucosal delivery systems designed to enhance the immune response following mucosal immunization have been evaluated for efficacy in tuberculosis vaccines [4] [5] . However, to our knowledge, none using live viable vaccines.
Live vaccines, such as BCG, provide several important advantages over other strategies, as they act like the natural infection, being readily uptaken by specialized antigen As a nasal carrier system, chitosan microparticles are ideal, due to their mucoadhesive and adjuvant properties, and ability to act as antigen depot, enabling a better interaction between the carried vaccine and the membrane epithelium, thus, allowing a more efficient uptake by alveolar macrophages [6] . IT .
GOALS
A particle-mediated delivery system of chitosan and alginate was designed via a mild ionotropic gelation procedure with sodium tripolyphosphate (TPP), as previously described Ill.
MATERIALS AND METHODS

A. Materials
Chitosan of different molecular weight (low molecular weight (CH-LMW, 150 kDa), medium molecular weight (CH MMW, 450 kDa), and high molecular weight (CH-HMW, 600 kDa)), sodium alginate with different viscosities, and TPP were obtained from Sigma Aldrich, UK.
Both BCG strains used in this study -M. bovis BCG Pasteur (ATCC35734) and a recombinant M. bovis BCG harbouring a pMN437 plasmid [11] , were kindly supplied by Prof Elsa Anes (FFUL). All cell culture reagents were from Invitrogen, UK.
B. Animals
Female BALB/c mice (n=4/group), 6-8 weeks old provided with food and drink ad libitum, were used in the immunization studies, which were performed in strict accordance with Serum specific IgG, IgG 1, IgG2a antibodies were detected by ELISA using a purified protein derivative (PPD) bovine tuberculin, which was probed with serum samples. Titres are reported as the reciprocal of serum dilutions that gave an optical density 5% higher than the strongest negative control reading.
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RESULTS AND DISCUSSION
A. Microparticles characterization
Three different vaccine delivery systems were produced:
BCG ressuspended in 0.9% NaCI only was used for i.n. and s.c. vaccination; BCG ressuspended in 0.25 mg/ml chitosan and BCG encapsulated in CS/Alg/TPP microparticles were employed as i.n. immunization agent. These systems characteristics are summarized in Table 1 . Table 2 . Ratios depict the titre oflgG2a divided by the titre ofigG 1. Any ratio >1 is associated with a predominant Th 1 response and any ratio <1 is associated with a predominant Th2 response.
C. immunization studies
Mice that were intranasally vaccinated with BCG only or BCG/CS developed higher levels of TgG2a ( • BCG Ln.
• BCG/CS Ln.
• BCG/CS/ALGITPP Ln. .BCGs.c. VI.
PLANNED DEVELOPMENTS
Further studies include assessment of mucosal immunity response by measurement of characteristics Th 1 ITh2 cytokine levels and TgA, related to mucosal immune response.
